Hypertension
📧 Sign up to get email alerts when something new happens for Hypertension.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2019-09-18Clinical Trial Update: Piloting Healthcare Coordination in Hypertension [NA]
Clinical trial update on piloting healthcare coordination in hypertension; completed with results posted.
-
FDA approval · 2019-09-17FDA Approved: THALITONE — Supplemental Application (Casper Pharma LLC)
The FDA approved a supplemental application for THALITONE (chlorthalidone) submitted by Casper Pharma LLC.
-
FDA approval · 2019-09-17FDA Approved: OLMESARTAN MEDOXOMIL — Original Application (Micro Labs Limited)
FDA approved the original application for olmesartan medoxomil from Micro Labs Limited, establishing a generic version of the antihypertensi…
-
FDA approval · 2019-09-17FDA Approved: OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE — Original Application (Lifestar Pharma LLC)
The FDA approved a generic combination tablet of olmesartan medoxomil and hydrochlorothiazide for hypertension. The applicant is Lifestar Ph…
-
CLINICAL_TRIALS trial_result · 2019-09-17Clinical Trial Update: Does Allopurinol Reduce Thickening of the Left Ventricle of the Heart in Patient With Treated Hypertension? [Phase 4]
Phase 4 trial evaluating whether allopurinol reduces left ventricular hypertrophy in patients with treated hypertension.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2019-09-13FDA Approved: VALSARTAN — Supplemental Application (Alembic Pharmaceuticals Limited)
The FDA approved a supplemental application for valsartan from Alembic Pharmaceuticals Limited (ANDA 091367).
-
FDA approval · 2019-09-13FDA Approved: NADOLOL — Original Application (VGYAAN Pharmaceuticals LLC)
The FDA approved Nadolol as a generic product through an Original Application (ANDA) from VGYAAN Pharmaceuticals LLC. Nadolol is a non-selec…
-
FDA approval · 2019-09-10FDA Approved: VALSARTAN AND HYDROCHLOROTHIAZIDE — Supplemental Application (Alembic Pharmaceuticals Limited)
FDA granted a supplemental approval for the generic fixed-dose combination product valsartan and hydrochlorothiazide by Alembic Pharmaceutic…
-
FDA approval · 2019-09-09FDA Approved: TELMISARTAN AND AMLODIPINE — Supplemental Application (Mylan Pharmaceuticals Inc.)
The FDA approved a supplemental application for telmisartan and amlodipine from Mylan Pharmaceuticals, enabling the generic combination prod…
-
FDA approval · 2019-09-06FDA Approved: VALSARTAN AND HYDROCHLOROTHIAZIDE — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for a generic fixed-dose combination of valsartan and hydrochlorothiazide by Mylan Pharmaceuticals, …
-
CLINICAL_TRIALS trial_result · 2019-09-06Clinical Trial Update: Chinese Medicine Treat for Hypertensive Renal Injury [Phase 2, Phase 3]
A phase 2/3 clinical trial update for a Chinese medicine treatment targeting hypertensive renal injury is in early unknown status.
-
CLINICAL_TRIALS trial_result · 2019-09-06Clinical Trial Update: Effect of Aliskiren and Hydrochlorothiazide on Kidney Oxygenation in Patients With Hypertension [Phase 4]
Phase 4 clinical trial evaluating the effect of aliskiren combined with hydrochlorothiazide on kidney oxygenation in patients with hypertens…
-
FDA approval · 2019-09-05FDA Approved: VALSARTAN AND HYDROCHLOROTHIAZIDE — Supplemental Application (Lupin Pharmaceuticals, Inc.)
The FDA approved a supplemental application for Lupin Pharmaceuticals' valsartan and hydrochlorothiazide combination, making this generic pr…
-
FDA approval · 2019-09-04FDA Approved: VALSARTAN — Supplemental Application (Macleods Pharmaceuticals Limited)
The FDA approved a supplemental application for VALSARTAN submitted by Macleods Pharmaceuticals Limited, indicating approval of changes to t…
-
CLINICAL_TRIALS trial_result · 2019-09-04Clinical Trial Update: Renal Artery Denervation In Addition to Catheter Ablation To Eliminate Atrial Fibrillation [Phase 3]
Phase 3 trial assessing renal artery denervation in addition to catheter ablation for atrial fibrillation, completed.
-
FDA approval · 2019-09-03FDA Approved: VALSARTAN — Supplemental Application (Lupin Pharmaceuticals, Inc.)
FDA approved Lupin Pharmaceuticals' supplemental application for valsartan, a generic angiotensin II receptor blocker, for approved labeling…
-
FDA approval · 2019-09-03FDA Approved: VALSARTAN — Supplemental Application (SQUARE PHARMACEUTICALS LIMITED)
FDA approved a supplemental application for valsartan submitted by Square Pharmaceuticals Limited. This approval pertains to the generic pro…
-
CLINICAL_TRIALS trial_result · 2019-08-21Clinical Trial Update: Clinical Study to Evaluate Adherence Improvement Fixed-dose Combination of Olostar Tab. in Patients With Hypertension and Dyslipidemia [Phase 4]
Phase 4 clinical trial update evaluating adherence-improving fixed-dose combination therapy of Olostar in patients with hypertension and dys…
-
CLINICAL_TRIALS trial_result · 2019-08-21Clinical Trial Update: Effects of the Beta-blocker Nebivolol (Bystolic) on Subjects With High Normal Blood Pressure and/or a Family History of Hypertension [Phase 4]
Phase 4 trial update on the beta-blocker nebivolol for individuals with high normal blood pressure and/or a family history of hypertension; …
-
FDA approval · 2019-08-20FDA Approved: VALSARTAN AND HYDROCHLOROTHIAZIDE — Supplemental Application (Macleods Pharmaceuticals Limited)
FDA approved a supplemental application for the generic combination valsartan and hydrochlorothiazide from Macleods Pharmaceuticals Limited.
-
FDA approval · 2019-08-20FDA Approved: VALSARTAN — Supplemental Application (Unichem Pharmaceuticals (USA), Inc.)
The FDA approved a supplemental application for VALSARTAN submitted by Unichem Pharmaceuticals (USA), Inc.
-
FDA approval · 2019-08-19FDA Approved: AMLODIPINE AND VALSARTAN — Supplemental Application (Lupin Pharmaceuticals, Inc.)
The FDA approved Lupin Pharmaceuticals' supplemental application for a fixed-dose combination of amlodipine and valsartan.
-
FDA approval · 2019-08-16FDA Approved: VALSARTAN AND HYDROCHLOROTHIAZIDE — Supplemental Application (Aurobindo Pharma Limited)
The FDA approved a supplemental application for a generic valsartan/hydrochlorothiazide combination tablet from Aurobindo Pharma Limited for…
-
FDA approval · 2019-08-16FDA Approved: IRBESARTAN — Supplemental Application (Camber Pharmaceuticals, Inc.)
The FDA approved a supplemental application for Irbesartan from Camber Pharmaceuticals, indicating an approved change to the existing ANDA a…
-
CLINICAL_TRIALS withdrawal · 2019-08-14Clinical Trial Update: The Efficacy and Safety of Cleviprex in Ventriculostomy Patients Requiring IV Antihypertensive Therapy [Phase 4]
Phase 4 trial of Cleviprex in ventriculostomy patients requiring IV antihypertensive therapy was withdrawn.